AVONCares Offers Aid to Underserved Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

NEW YORK-Cancer Care, Inc. has established a new program-The AVONCares Program for Medically Underserved Women-through a generous gift from The Avon Products Foundation. The program will provide financial assistance and relevant education and support to low-income, underinsured and uninsured, underserved women throughout the country in need of diagnostic and/or related services for the treatment of breast, cervical, and ovarian cancers.

NEW YORK—Cancer Care, Inc. has established a new program—The AVONCares Program for Medically Underserved Women—through a generous gift from The Avon Products Foundation. The program will provide financial assistance and relevant education and support to low-income, underinsured and uninsured, underserved women throughout the country in need of diagnostic and/or related services for the treatment of breast, cervical, and ovarian cancers.

The AVONCares Program will allow Cancer Care to provide financial assistance to help women pay for:

Diagnostic (postscreening) services that lead to definitive diagnoses for women who have had breast, cervical, and ovarian cancer screenings.

Transportation to and from treatment.

Childcare for women with families.

An escort to accompany older women to and from diagnostic workup and treatment.

Services offered to women through the AVONCares program will be accessible nationwide through Cancer Care’s toll-free line 1-800-813-HOPE (4673), via the Internet (www.cancercare.org), and at Cancer Care offices in the New York metropolitan area, New Jersey, and Connecticut.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.